-
公开(公告)号：US10653713B2
公开(公告)日：2020-05-19
申请号：US13267243
申请日：2011-10-06
Applicant: Deepak Ramesh Thakker , Lisa L. Shafer , Greg Stewart
Inventor： Deepak Ramesh Thakker , Lisa L. Shafer , Greg Stewart
Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.
-
公开(公告)号：US09040045B2
公开(公告)日：2015-05-26
申请号：US12120269
申请日：2008-05-14
Applicant: Lisa Lynn Shafer , Deepak Ramesh Thakker
Inventor： Lisa Lynn Shafer , Deepak Ramesh Thakker
CPC classification number: C07K16/18 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/54
Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include Aβ, and the methods, agents and devices are useful for reducing the accumulation of Aβ, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to Aβ, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to Aβ, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.
Abstract translation: 描述了用于治疗患者以减少某些蛋白质在脑中积聚的方法，试剂和装置。 这样的蛋白质包括A＆bgr;并且所述方法，试剂和装置可用于减少与诸如阿尔茨海默病（AD）之类的疾病相关的斑块的主要成分的A＆bgr的积累。 A系统的抗体，当全身或直接递送到中枢神经系统时，改善AD转基因小鼠模型中的认知缺陷。 然而，与A＆bgr抗体的周边不同，其增加脑血管斑块和出血，直接中央给药不会导致脑血管斑块和出血的这种增加。
-
公开(公告)号：US20100298762A1
公开(公告)日：2010-11-25
申请号：US12468685
申请日：2009-05-19
Applicant: Deepak Ramesh Thakker , Carl A. Schu , Eric Neal Burright , Paul W. Wacnik , Jennifer M. Heisel , Lothar Krinke
Inventor： Deepak Ramesh Thakker , Carl A. Schu , Eric Neal Burright , Paul W. Wacnik , Jennifer M. Heisel , Lothar Krinke
IPC: A61K31/7088 , C12N13/00 , A61N1/30 , A61M37/00
Abstract: The instant invention provides a method for improving efficiency of RNA delivery to cells. The method comprises applying a low strength electric field to the cells and then after a certain time period, administering the ribonucleic acid sequence to the cells. Devices, kits, and RNA molecules suitable for delivery and devices suitable for practicing the disclosed methods are also provided.
Abstract translation: 本发明提供了一种提高RNA递送细胞效率的方法。 该方法包括向细胞施加低强度电场，然后在一定时间后，向细胞施用核糖核酸序列。 还提供了适合于递送的装置，试剂盒和RNA分子以及适用于实施所公开方法的装置。
-
4.发明申请Compositions and Methods for Making Therapies Delivered by Viral Vectors Reversible for Safety and Allele-Specificity 有权由病毒载体产生治疗的组合物和方法可逆的安全性和等位基因特异性公开(公告)号：US20100284990A1
公开(公告)日：2010-11-11
申请号：US12580996
申请日：2009-10-16
Applicant: William F. Kaemmerer , Eric Burright , Deepak Ramesh Thakker , Jennifer Heisel
Inventor： William F. Kaemmerer , Eric Burright , Deepak Ramesh Thakker , Jennifer Heisel
CPC classification number: A61K31/70 , A61K48/005 , A61K48/0066 , C12N2799/025 , C12N2800/30
Abstract: The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.
Abstract translation: 本发明涉及用于调节亨廷顿病基因疗法的组合物，方法和试剂盒，包括但不限于可逆基因治疗和等位基因特异性疗法。
-
公开(公告)号：US20080213349A1
公开(公告)日：2008-09-04
申请号：US12046346
申请日：2008-03-11
Applicant: Deepak Ramesh Thakker , Michael Eric Benz
Inventor： Deepak Ramesh Thakker , Michael Eric Benz
CPC classification number: A61K47/6913 , A61K47/6911
Abstract: Liposome complexes are provided for site-specific delivery of pharmaceutical agents with improved targeting efficiency. The liposome complexes include a pharmaceutical agent associated with the liposome; a sialic acid-containing molecule associated with the liposome; and optionally a targeting agent attached to the sialic acid-containing molecule. The invention also provides methods of making liposome complexes and their in vivo administration.
Abstract translation: 提供脂质体复合物用于具有改善的靶向效率的药剂的位点特异性递送。 脂质体复合物包括与脂质体相关的药剂; 与脂质体相关的含唾液酸的分子; 和任选的连接到含唾液酸分子的靶向剂。 本发明还提供了制备脂质体复合物及其体内给药的方法。
-
Patent Agency Ranking
公开(公告)号：US08207138B2
公开(公告)日：2012-06-26
申请号：US12468685
申请日：2009-05-19
Applicant: Deepak Ramesh Thakker , Carl A. Schu , Eric Neal Burright , Paul W. Wacnik , Jennifer M. Heisel , Lothar Krinke
Inventor： Deepak Ramesh Thakker , Carl A. Schu , Eric Neal Burright , Paul W. Wacnik , Jennifer M. Heisel , Lothar Krinke
IPC: C12N15/11
Abstract: The instant invention provides a method for improving efficiency of RNA delivery to cells. The method comprises applying a low strength electric field to the cells and then after a certain time period, administering the ribonucleic acid sequence to the cells. Devices, kits, and RNA molecules suitable for delivery and devices suitable for practicing the disclosed methods are also provided.
Abstract translation: 本发明提供了一种提高RNA递送细胞效率的方法。 该方法包括向细胞施加低强度电场，然后在一定时间后，向细胞施用核糖核酸序列。 还提供了适合于递送的装置，试剂盒和RNA分子以及适用于实施所公开方法的装置。
-
7.发明授权Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof 有权包含RNAi剂和神经营养因子的治疗组合物及其使用方法公开(公告)号：US08173614B2
公开(公告)日：2012-05-08
申请号：US12580973
申请日：2009-10-16
Applicant: Eric Neal Burright , William F. Kaemmerer , Deepak Ramesh Thakker , Jennifer Heisel
Inventor： Eric Neal Burright , William F. Kaemmerer , Deepak Ramesh Thakker , Jennifer Heisel
CPC classification number: A61K31/7088 , A61K38/00 , C07K14/475
Abstract: The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.
Abstract translation: 本发明提供了用于治疗亨廷顿舞蹈症的新型组合疗法，其包括a）BDNF或其合适的片段和b）能够引起负责神经变性疾病的基因的抑制的药剂。 本发明提供了适用于这些组合疗法的应用的核酸序列，方法和系统。
-
公开(公告)号：US20120087869A1
公开(公告)日：2012-04-12
申请号：US13267243
申请日：2011-10-06
Applicant: Deepak Ramesh Thakker , Lisa L. Shafer , Greg Stewart
Inventor： Deepak Ramesh Thakker , Lisa L. Shafer , Greg Stewart
CPC classification number: A61K31/711 , A61K49/105 , A61K49/143 , A61M5/14276 , A61M5/16804 , A61M2205/50 , A61M2210/0693
Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.
Abstract translation: 通过以小于500微升/小时的流速（例如约2微升/小时至约100微升/小时）将液体制剂中的试剂递送至CSF，可以实现药剂的广泛脑脊液（CSF）分布。
-
9.发明申请Therapeuting Compositions Comprising an RNAi Agent and a Neurotrophic Factor and Methods of Use Thereof 有权包含RNAi剂和神经营养因子的组合物及其使用方法公开(公告)号：US20100113351A1
公开(公告)日：2010-05-06
申请号：US12580973
申请日：2009-10-16
Applicant: Eric Neal Burright , William F. Kaemmerer , Deepak Ramesh Thakker , Jennifer Heisel
Inventor： Eric Neal Burright , William F. Kaemmerer , Deepak Ramesh Thakker , Jennifer Heisel
IPC: A61K31/7088 , C12N5/10 , C12N1/21 , C12N1/19 , A61K38/17 , C07H21/04 , A01K67/00 , A01K67/027 , A61P25/22
CPC classification number: A61K31/7088 , A61K38/00 , C07K14/475
Abstract: The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.
Abstract translation: 本发明提供了用于治疗亨廷顿舞蹈症的新型组合疗法，其包括a）BDNF或其合适的片段和b）能够引起负责神经变性疾病的基因的抑制的药剂。 本发明提供了适用于这些组合疗法的应用的核酸序列，方法和系统。
-
公开(公告)号：US20080286330A1
公开(公告)日：2008-11-20
申请号：US12120269
申请日：2008-05-14
Applicant: Lisa Lynn Shafer , Deepak Ramesh Thakker
Inventor： Lisa Lynn Shafer , Deepak Ramesh Thakker
IPC: A61F2/00 , A61K39/395
CPC classification number: C07K16/18 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/54
Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include Aβ, and the methods, agents and devices are useful for reducing the accumulation of Aβ, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to Aβ, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to Aβ, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.
Abstract translation: 描述了用于治疗患者以减少某些蛋白质在脑中积聚的方法，试剂和装置。 这种蛋白质包括Abeta，并且所述方法，试剂和装置可用于减少作为阿尔茨海默氏病（AD）疾病相关斑块的主要成分的Abeta的积累。 Abeta的抗体，当全身或直接递送到中枢神经系统时，改善AD转基因小鼠模型中的认知缺陷。 然而，与增加脑血管斑块和出血的Abeta抗体的周边不同，直接中央给药不会导致脑血管斑块和出血的这种增加。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.018 seconds)
